Identification Generic Name (2R)-2-(3-Biphenylyl)-N-{(2R)-2-hydroxy-3-[(2-pyridinylsulfonyl)amino]propyl}-4-methylpentanamide DrugBank Accession Number DB04244 Background Not Available Type Small Molecule Groups Experimental Structure 
 
 
 3D Download  MOL SDF 3D-SDF PDB SMILES InChI 
 
 
  Similar Structures Structure for (2R)-2-(3-Biphenylyl)-N-{(2R)-2-hydroxy-3-[(2-pyridinylsulfonyl)amino]propyl}-4-methylpentanamide (DB04244) ×  Close Weight Average: 481.607  Monoisotopic: 481.203527185  Chemical Formula C 26 H 31 N 3 O 4 S Synonyms Not Available Pharmacology Indication Not Available Reduce drug development failure rates Build, train, & validate machine-learning models with evidence-based and structured datasets. See how     Build, train, & validate predictive machine-learning models with structured datasets. See how Contraindications & Blackbox Warnings Avoid life-threatening adverse drug events Improve clinical decision support with information on  contraindications & blackbox warnings, population restrictions, harmful risks, & more. Learn more     Avoid life-threatening adverse drug events & improve clinical decision support. Learn more Pharmacodynamics Not Available Mechanism of action Target Actions Organism U Cathepsin K Not Available Humans Absorption Not Available Volume of distribution Not Available Protein binding Not Available Metabolism Not Available Route of elimination Not Available Half-life Not Available Clearance Not Available Adverse Effects Improve decision support & research outcomes With structured adverse effects data, including:  blackbox warnings, adverse reactions, warning & precautions, & incidence rates. Learn more     Improve decision support & research outcomes with our structured adverse effects data. Learn more Toxicity Not Available Pathways Not Available Pharmacogenomic Effects/ADRs  
 
 
 Not Available Interactions Drug Interactions  
 
 
 This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.  Not Available Food Interactions Not Available Categories Drug Categories Not Available Chemical Taxonomy Provided by  Classyfire Description This compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond. Kingdom Organic compounds Super Class Benzenoids Class Benzene and substituted derivatives Sub Class Biphenyls and derivatives Direct Parent Biphenyls and derivatives Alternative Parents Pyridinesulfonamides  /  Phenylacetamides  /  Organosulfonamides  /  N-acyl amines  /  Heteroaromatic compounds  /  Aminosulfonyl compounds  /  Secondary carboxylic acid amides  /  Secondary alcohols  /  Azacyclic compounds  /  Organonitrogen compounds  /  Organic oxides  /  Hydrocarbon derivatives  /  Carbonyl compounds 
 
 
  show 3 more Substituents Alcohol  /  Aminosulfonyl compound  /  Aromatic heteromonocyclic compound  /  Azacycle  /  Biphenyl  /  Carbonyl group  /  Carboxamide group  /  Carboxylic acid derivative  /  Fatty acyl  /  Fatty amide  /  Heteroaromatic compound  /  Hydrocarbon derivative  /  N-acyl-amine  /  Organic nitrogen compound  /  Organic oxide  /  Organic oxygen compound  /  Organic sulfonic acid or derivatives  /  Organoheterocyclic compound  /  Organonitrogen compound  /  Organooxygen compound  /  Organosulfonic acid amide  /  Organosulfonic acid or derivatives  /  Organosulfur compound  /  Phenylacetamide  /  Pyridine  /  Pyridine-2-sulfonamide  /  Secondary alcohol  /  Secondary carboxylic acid amide  /  Sulfonyl 
 
 
  show 19 more Molecular Framework Aromatic heteromonocyclic compounds External Descriptors Not Available Affected organisms Not Available Chemical Identifiers UNII Not Available CAS number Not Available InChI Key YCDHZDINQZLSRR-DNQXCXABSA-N InChI InChI=1S/C26H31N3O4S/c1-19(2)15-24(22-12-8-11-21(16-22)20-9-4-3-5-10-20)26(31)28-17-23(30)18-29-34(32,33)25-13-6-7-14-27-25/h3-14,16,19,23-24,29-30H,15,17-18H2,1-2H3,(H,28,31)/t23-,24-/m1/s1 IUPAC Name (2R)-2-{[1,1'-biphenyl]-3-yl}-N-[(2R)-2-hydroxy-3-(pyridine-2-sulfonamido)propyl]-4-methylpentanamide SMILES [H]N(C[C@@H](O)CN([H])S(=O)(=O)C1=CC=CC=N1)C(=O)[C@H](CC(C)C)C1=CC=CC(=C1)C1=CC=CC=C1 References General References Not Available External Links PubChem Compound 5288593 PubChem Substance 46506469 ChemSpider 4450723 ZINC ZINC000003870500 PDBe Ligand I10 PDB Entries 1bgo Clinical Trials Clinical Trials  
 
 
 Phase Status Purpose Conditions Count Pharmacoeconomics Manufacturers Not Available Packagers Not Available Dosage Forms Not Available Prices Not Available Patents Not Available Properties State Solid Experimental Properties Not Available Predicted Properties Property Value Source Water Solubility 0.00252 mg/mL ALOGPS logP 2.81 ALOGPS logP 3.77 Chemaxon logS -5.3 ALOGPS pKa (Strongest Acidic) 8.86 Chemaxon pKa (Strongest Basic) -0.73 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 108.39 Å 2 Chemaxon Rotatable Bond Count 10 Chemaxon Refractivity 132.81 m 3 ·mol -1 Chemaxon Polarizability 52.53 Å 3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon Predicted ADMET Features Property Value Probability Human Intestinal Absorption + 0.9471 Blood Brain Barrier - 0.6459 Caco-2 permeable - 0.6724 P-glycoprotein substrate Substrate 0.5 P-glycoprotein inhibitor I Non-inhibitor 0.5334 P-glycoprotein inhibitor II Non-inhibitor 0.8792 Renal organic cation transporter Non-inhibitor 0.9353 CYP450 2C9 substrate Non-substrate 0.7419 CYP450 2D6 substrate Non-substrate 0.8049 CYP450 3A4 substrate Non-substrate 0.5771 CYP450 1A2 substrate Non-inhibitor 0.8717 CYP450 2C9 inhibitor Non-inhibitor 0.6566 CYP450 2D6 inhibitor Non-inhibitor 0.8749 CYP450 2C19 inhibitor Non-inhibitor 0.6275 CYP450 3A4 inhibitor Non-inhibitor 0.6154 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7382 Ames test Non AMES toxic 0.682 Carcinogenicity Non-carcinogens 0.5806 Biodegradation Not ready biodegradable 0.9932 Rat acute toxicity 2.4446 LD50, mol/kg  Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9927 hERG inhibition (predictor II) Non-inhibitor 0.6826    ADMET data is predicted using  admetSAR , a free tool for evaluating chemical ADMET properties. ( 23092397 )  Spectra Mass Spec (NIST) Not Available Spectra Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available Targets Build, predict & validate machine-learning models Use our structured and evidence-based datasets to  unlock newinsights and accelerate drug research. Learn more     Use our structured and evidence-based datasets to unlock new insights and accelerate drug research. Learn more 
 
 
  Details 1.  Cathepsin K Kind Protein Organism Humans Pharmacological action Unknown General Function Proteoglycan binding Specific Function Closely involved in osteoclastic bone resorption and may participate partially in the disorder of bone remodeling. Displays potent endoprotease activity against fibrinogen at acid pH. May play an i... Gene Name CTSK Uniprot ID P43235 Uniprot Name Cathepsin K Molecular Weight 36965.82 Da References Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [ Article ]  Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [ Article ]  Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [ Article ]  × Identify potential medication risks Easily compare up to 40 drugs with our drug interaction checker. Get severity rating, description, and management advice.  Learn more      Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52 